To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.

Inclusion Criteria:

• Patients with subfoveal predominantly classic, minimally classic and purely occult lesions, secondary to age related macular degeneration, with a total lesion size (including blood, atrophy/scar and neovascularization) of < 12 total disc areas, of which at least 50% are active CNV.
• Patients must have visual acuity 20/50 to 20/320 in the study eye.
• Patients must have better visual acuity in the fellow eye than the study eye.
• Subretinal hemorrhage (if any) must comprise no more than 50% of total lesion size.

Exclusion Criteria:

• Patients with concomitant eye disease, including glaucoma, uveitis, diabetic retinopathy, presence of pigment epithelial tears or rips, acute ocular or periocular infection in the study eye.
• Patients with > 3 prior PDT treatments with Visudyne in the study eye.
• Patients who received PDT in the study eye within eight weeks prior to the baseline angiography/photography.